Connect with us

Health

New STRENGTH Analysis Reignites Debate on Omega-3 CV Benefits – Medscape

The new analysis showing no benefits linked to higher achieved levels of EPA casts doubt over the use of high-dose omega-3 fatty acid products for preventing cardiovascular…

Published

on

Article feature image

Questions over the cardiovascular benefits shown in the REDUCE-IT trial with icosapent ethyl, a high-dose eicosapentaenoic acid (EPA) product, have been reignited with a new analysis from the STRENGTH trial showing no benefit of a high-dose combined omega-3 fatty acid product in patients who achieved the highest EPA levels and no harm in those with the highest levels of docosahexaenoic acid (DHA).
STRENGTH investigator Steven Nissen, MD, said these new results add to concerns about the positive…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Plasma therapy boosts survival in Covid patients with blood cancers – The Tribune India
Article feature image
Convalescent plasma associated with better survival in blood cancer patients with COVID-19 – News-Medical.Net